Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Asthenia
ADR ID BADD_A00362
ADR Hierarchy
08      General disorders and administration site conditions
08.01      General system disorders NEC
08.01.01      Asthenic conditions
08.01.01.001      Asthenia
Description Clinical sign or symptom manifested as debility, or lack or loss of strength and energy. [MeSH]
MedDRA Code 10003549
MeSH ID D001247; D009440; D000073496
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Adynamia | Asthenia | Collapse of legs | Debility | Debility marked | Debility, unspecified | Feeling of total lack of energy | Feelings of weakness | General debility | Loss of energy | Nervous debility | Neurasthaenia | Neurasthenia | Strength loss of | Weakness | Weakness generalised | Weakness generalized | Weakness postural | Energy decreased | Frailty | Weakness worsened | Hyposthenia | Cerebro-asthenic syndrome
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01261Leuprolide monoacetate--
BADD_D01262Levalbuterol--
BADD_D01263Levalbuterol hydrochloride--
BADD_D01265Levetiracetam--
BADD_D01267Levobunolol--
BADD_D01268Levobunolol hydrochloride--
BADD_D01269Levobupivacaine--
BADD_D01270Levocabastine hydrochloride--
BADD_D01271Levocarnitine--
BADD_D01272Levocetirizine0.000194%
BADD_D01273Levocetirizine dihydrochloride--
BADD_D01274Levodopa-4'-monophosphate--
BADD_D01275Levofloxacin0.002151%
BADD_D01276Levoleucovorin--
BADD_D01281Levonorgestrel--
BADD_D01282Levorphanol-
BADD_D01285Levothyroxine0.000818%
BADD_D01287Lidocaine--
BADD_D01291Linaclotide--
BADD_D01295Linezolid0.038530%
BADD_D01296Liothyronine0.001520%
BADD_D01298Liraglutide--
BADD_D01299Lisdexamfetamine dimesylate--
BADD_D01300Lisinopril--
BADD_D01301Lisuride--
BADD_D01303Lithium carbonate0.003587%
BADD_D01304Lithium cation0.002477%
BADD_D01305Lithium hydroxide--
BADD_D01307Lodoxamide--
BADD_D01309Lomefloxacin--
The 23th Page    First    Pre   23 24 25 26 27    Next   Last    Total 47 Pages
ADReCS-Target
ADR Term Drug Name Target